Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

Phase 3

Active, not recruiting

Conditions: Non-Hodgkin Lymphoma

Interventions: Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy

First Posted Date: 2018-06-27

Last Posted Date: 2025-05-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 331

Registration Number: NCT03570892

Locations: 🇺🇸
Moores UC San Diego Cancer Center, La Jolla, California, United States
🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸
UCSF Medical Center, San Francisco, California, United States

and more 25 locations

Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma

Phase 2

Active, not recruiting

Conditions: Follicular Lymphoma

Interventions: Biological: tisagenlecleucel

First Posted Date: 2018-06-26

Last Posted Date: 2025-05-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 98

Registration Number: NCT03568461

Locations: 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
UCSF Medical Center, San Francisco, California, United States
🇺🇸
H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

and more 8 locations

A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients

Phase 2

Completed

Conditions: Multiple Sclerosis

Interventions: Combination Product: ofatumumab with AI
Combination Product: ofatumumab with PRF

First Posted Date: 2018-06-18

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 284

Registration Number: NCT03560739

Locations: 🇪🇸
Novartis Investigative Site, Castilleja de la cuesta, Sevilla, Spain

Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab

Phase 2

Completed

Conditions: Chronic Plaque-type Psoriasis

Interventions: Procedure: Skin biopsies

First Posted Date: 2018-06-12

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT03553823

Locations: 🇩🇪
Novartis Investigative Site, Selters, Germany

Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes

Phase 3

Completed

Conditions: Malignant Melanoma

Interventions: Drug: Dabrafenib
Drug: Trametinib

First Posted Date: 2018-06-11

Last Posted Date: 2025-04-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 552

Registration Number: NCT03551626

Locations: 🇬🇧
Novartis Investigative Site, Southampton, United Kingdom

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

Phase 1

Terminated

Conditions: Non-small Cell Lung Cancer (NSCLC)
Triple Negative Breast Cancer (TNBC)
Pancreatic Ductal Adenocarcinoma (PDAC)
Colorectal Cancer Microsatellite Stable (MSS)
Ovarian Cancer
Renal Cell Carcinoma (RCC)
Metastatic Castration Resistant Prostate Cancer (mCRPC)

Interventions: Other: NZV930
Other: PDR001
Drug: NIR178

First Posted Date: 2018-06-07

Last Posted Date: 2024-12-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 127

Registration Number: NCT03549000

Locations: 🇬🇧
Novartis Investigative Site, Sutton, Surrey, United Kingdom
🇺🇸
University of Texas MD Anderson Cancer Center MD Anderson PSC, Houston, Texas, United States
🇺🇸
H Lee Moffitt Cancer Center and Research Institute Inc, Tampa, Florida, United States

Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations

Phase 3

Withdrawn

Conditions: Carcinoma, Non-small Cell Lung

Interventions: Drug: EFG816
Drug: erlotinib or gefitinib

First Posted Date: 2018-05-18

Last Posted Date: 2019-11-22

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03529084

Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.

Phase 4

Completed

Conditions: Renal Angiomyolipoma

Interventions: Drug: Everolimus

First Posted Date: 2018-05-16

Last Posted Date: 2021-09-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT03525834

Locations: 🇨🇳
Novartis Investigative Site, Beijing, China

A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP

Phase 2

Completed

Conditions: Immune Thrombocytopenic Purpura (ITP)

Interventions: Drug: eltrombopag

First Posted Date: 2018-05-15

Last Posted Date: 2025-01-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 105

Registration Number: NCT03524612

Locations: 🇺🇸
Hematology Oncology Association of Rockland, Nyack, New York, United States
🇺🇸
Case Western Reserve, Cleveland, Ohio, United States
🇬🇧
Novartis Investigative Site, London, United Kingdom

A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis

Phase 2

Terminated

Conditions: Atopic Dermatitis

Interventions: Drug: ZPL389 50mg
Drug: ZPL389 10mg
Drug: Placebo
Drug: ZPL389 3mg
Drug: ZPL389 30mg

First Posted Date: 2018-05-07

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 293

Registration Number: NCT03517566

Locations: 🇬🇧
Novartis Investigative Site, Portsmouth, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy